The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Investigating the Potential effect of Peroxisome Proliferation in Diminishing Alpha-synuclein Pathogenesis
Objective/Rationale:
Alpha-synuclein is a protein critically involved in the pathogenesis of Parkinson’s disease. Growing evidence link alpha-synuclein pathogenesis in PD and brain lipid metabolism... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Image-Guided Convective Delivery of AAV Vectors
Objective/Rationale:
Gene transfer technology holds promise to permanently alter the natural course of PD. However, in order for this technology to work there is a critical need for safe, reproducible... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Convection Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Human Parkinson's disease
Objective/Rationale:
Infusion of neuroactive drugs into targeted nuclei of the basal ganglia involved in Parkinson’s disease should provide critical insight into the role of neurotransmitters in these... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Real-time Monitoring of Targeting, Delivery and Spread of Therapeutic Agents in the Brain
Objective/Rationale:
Current drug therapy for Parkinson’s disease has limited long term effectiveness. To improve therapy in the future, delivery of therapeutic agents to the brain will be an... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Deep brain imaging to determine movement of compounds relevant to Parkinson's disease
Objective/Rationale:
Clinical trials with a number of agents suggest that the ability of compounds to move through the interstitial spaces of the brain is a critical factor for their effectiveness... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Novel Antibodies for the Delivery of Parkinson's Therapeutics
Objective/Rationale:
Hindering drug development for neurological diseases like Parkinson’s disease is a lack of robust drug delivery strategies that can target medicines to the brain noninvasively via...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.